Advertisement

Topics

Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC

2018-12-14 02:26:19 | BioPortfolio

Published on BioPortfolio: 2018-12-14T02:26:19-0500

Clinical Trials [6151 Associated Clinical Trials listed on BioPortfolio]

Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer

Lung cancer, the leading cause of cancer related mortality. Among them, non small cell lung cancer accounts for 85%. Only part of patients could be treated with radical surgery, and some p...

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in H...

NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

Patients with medically inoperable primary soft tissue lesion of the lung will have transbronchial microwave ablation performed via transbronchial approach by an interventional pulmonologi...

Microwave Ablation in Ground Glass Nodules

GGO was commonly observed recently.Radiofrequency ablation has been widely applied in the treatment of patients with GGO. No study had explored the microwave ablation in the treatment of G...

MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)

Does lung ablation improve clinical outcomes for patients deemed to be surgically high-risk?

PubMed Articles [33006 Associated PubMed Articles listed on BioPortfolio]

Microwave ablation followed by immediate biopsy in the treatment of non-small cell lung cancer.

To evaluate the efficacy and safety of microwave ablation (MWA) followed by immediate biopsy in the treatment of non-small cell lung cancer (NSCLC) and to clarify whether pathology changes can predict...

Microwave ablation with continued EGFR tyrosine kinase inhibitor therapy prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.

Although patients with EGFR-mutant non-small-cell lung cancer (NSCLC) benefit from treatment with EGFR-tyrosine kinase inhibitors (TKIs), outcomes are limited by the eventual development of acquired r...

Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC).

To assess the efficacy of maintenance pembrolizumab in extensive-stage small cell lung cancer (SCLC) patients, after treatment with platinum/etoposide.

Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.

Lung cancer is a major health concern worldwide, but new immunotherapeutic treatments for lung cancer have shown great promise and the prognosis for many severe cancers including lung cancer has been ...

Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.

Anti-PD-1 immunotherapy has dramatically shifted therapeutic perspectives for advanced non-small cell lung cancer (NSCLC). We assessed cost-effectiveness of anti-PD-1 antibody pembrolizumab compared t...

Medical and Biotech [MESH] Definitions

Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.

A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).

Removal of tissue by vaporization, abrasion, or destruction. Methods used include heating tissue by hot liquids or microwave thermal heating, freezing (CRYOABLATION), chemical ablation, and photoablation with LASERS.

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

A quinazoline derivative and ANTINEOPLASTIC AGENT that functions as a PROTEIN KINASE INHIBITOR for EGFR associated tyrosine kinase. It is used in the treatment of NON-SMALL CELL LUNG CANCER.

More From BioPortfolio on "Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial